2
Announcements
Trials
Browse
Landscape
Status
Completed
12
Recruiting
5
Active not recruiting
5
Withdrawn
4
Terminated
3
Suspended
1
Not yet recruiting
1
Available
1
Sponsor Class
INDUSTRY
1
Study Type
Expanded_access
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Lymphoma
1
Leukemia
1
Interventions
3-Iodobenzylguanidine
4
tempol
2
balstilimab
2
zolbetuximab
1
zipalertinib
1
venetoclax
1
ulixertinib
1
tisagenlecleucel
1
tipifarnib
1
tebentafusp
1
talazoparib
1
sodium thiosulfate
1
selinexor
1
ruxolitinib
1
ribociclib
1
osunprotafib
1
nirogacestat
1
mirdametinib
1
mifamurtide
1
lifileucel
1
leronlimab
1
idecabtagene vicleucel
1
gedatolisib
1
fluorodopa F 18
1
fluorocholine
1
epigallocatechin gallate
1
ensartinib
1
dodecyl maltoside
1
carbon-11 methionine
1
burosumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Available
×
tisagenlecleucel
×
Clear all
NCT03601442
2026-04-23
Managed Access Programs for CTL019, Tisagenlecleucel
Novartis
Available